Reminyl
(Galantamine)ApprovedSmall molecule
Galantamine is used to treat mild to moderate Alzheimer's disease by helping to improve memory and thinking skills. It works by increasing the levels of a chemical in the brain that helps nerve cells communicate with each other.[2] Reminyl is currently approved and in use across 19 indications[4].[1]
Reminyl is one of 428 small molecule programs targeting Memory. It is currently in Approved.
19
Indications
57
Total Trials
2
Active Trials
427
Competitors
3
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 18 indications
Competition
Competitive Landscape
350 competitors in Treatment
#DrugCompanyPhaseTrials
1Reminyl
WWim Janssens
Approved
Biltricide
BayerPreclinical
Dexilant
TakedaPreclinical
Alfenta
Jazz PharmaceuticalsPreclinical
Niclocide
BayerPreclinical
Minipress
PfizerPreclinical
Hivid
CConrado Roberto Hoffmann Filho
Preclinical
Valium
Akero TherapeuticsPreclinical
Lotemax
PPharmos
Preclinical
Norpramin
VValidus Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Alzheimer's Disease10 trials
Long-term Safety and Efficacy of Galantamine in Alzheimer's Disease
Completed·
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00304629·241 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00304629·241 enrolledShow 7 more trials
A Cardiac Safety Study of Galantamine in the Treatment of Alzheimer's Disease.
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00309725·139 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00309725·139 enrolledSchizophrenia5 trials
Cognitive impairment4 trials
Show 1 more trial
Cognitive Rehabilitation and Galantamine for Post Stroke Cognitive Impairment
Completed·IInstitut National de la Santé Et de la Recherche Médicale, France·Phase 2·NCT01508494·47 enrolled
Cognition3 trials
28 more indications
Homeostasis2 trials
Cognitive Function2 trials
Mild to Moderate Alzheimer's Disease2 trials
Headache1 trial
Galantamine in the Treatment of Post-Traumatic Headache
Unknown status·—·Phase 4·NCT00219869·30 enrolled
Single Dose1 trial
Executive Function1 trial
Galantamine Executive Function in Parkinson's Disease
Unknown status·—·N/A·NCT00211588·90 enrolled
Stroke1 trial
Vascular Dementia1 trial
Bipolar Disorder1 trial
Tardive Dyskinesia1 trial
Treatment of Tardive Dyskinesia With Galantamine
Completed·—·Phase 4·NCT00164242·36 enrolled
Endothelial Dysfunction1 trial
Central Nervous System1 trial
Alzheimer disease1 trial
Trauma1 trial
Cognitive REmediation After Trauma Exposure Trial = CREATE Trial
Terminated·IINTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium·Phase 2·NCT01416948·32 enrolled
Ischemic stroke1 trial
Interaction1 trial
Regulatory
FDA Approval Timeline[5]
Feb 28, 2001
RAZADYNE
NDA NDA021169
Jun 22, 2001
RAZADYNE
NDA NDA021224
Apr 1, 2005
RAZADYNE ER
NDA NDA021615
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Reminyl drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Galantamine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Acetylcholinesterase Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- WWim Janssens